Bovine Interleukin 6,IL-6 ELISA Kit
- Known as:
- Bovine Interleukin 6,Interleukin-6 Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- E0000BO
- Product Quantity:
- 48T
- Category:
- Elisa Kits
- Supplier:
- JING
- Gene target:
- Bovine Interleukin 6 IL-6 ELISA Kit
Related genes to: Bovine Interleukin 6,IL-6 ELISA Kit
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: Bovine Interleukin 6,IL-6 ELISA Kit
Related articles to: Bovine Interleukin 6,IL-6 ELISA Kit
- SARS-CoV-2 infection can induce a hyperinflammatory response through excessive cytokine release, contributing to disease severity and mortality. NRICM101, a government-endorsed multi-herbal traditional Chinese medicine formula, has shown promising immunomodulatory and antiviral effects in preclinical studies. However, clinical evidence on its effect on inflammatory biomarkers in COVID-19 patients remains limited. - Source: PubMed
Publication date: 2026/09/30
Wang Ying-ChuanYao Ya-HsinLin Sunny Jui-ShanChiu Chun-Hsiang - Intestinal inflammation severely restricts the healthy culture of grass carp. Although nucleotides (NT) and β-glucan (BG) exert immunoregulatory effects separately, their combined immunomodulatory mechanism in fish intestinal fibroblasts remains poorly understood. The present study aimed to investigate the effects of NT, BG and their combination on intestinal inflammatory responses and oxidative stress in lipopolysaccharide (LPS)-induced inflammatory models, and further evaluate their impacts on the Toll/NF-κB signaling pathway using grass carp (Ctenopharyngodon idella) intestinal fibroblasts. Fibroblasts were subjected to LPS-induced inflammation followed by individual or combined NT and BG supplementation. Results showed that NT and BG, either individually or in combination, significantly reduced the LPS-induced up-regulation of TNF-α and IL-6 gene expression and secretion, and reversed the LPS-induced reductions in SOD activity and T-AOC level, and inhibited the elevation of MDA content in intestinal fibroblasts (P < 0.05). Meanwhile, LPS stimulation significantly inhibited nrf2 expression but increased keap1 expression (P < 0.05). However, NT and/or BG significantly down-regulated LPS-induced keap1 expression (P < 0.05), yet failed to induce significant change in nrf2 levels (P > 0.05). Furthermore, NT and/or BG reversed LPS-regulated expression of multiple pro- and anti-inflammatory cytokines and suppressed excessive activation of the Toll/NF-κB signalling pathway. Notably, co-application of NT and BG produced combinatory protective benefits superior to single-agent treatments. Quantitative analysis showed that compared with NT-alone treatment, combined NT and BG treatment further improved the mitigation of inflammatory and oxidative-related indicators by 7.26% - 47.65%; compared with BG-alone treatment, the combined treatment yielded an additional improvement of 5.38% - 38.95% for these biomarkers. Collectively, these findings verify that NT and BG alleviate LPS-induced inflammatory injury in grass carp intestinal fibroblasts via restraining Toll/NF-κB signaling, and their combined treatment achieves more prominent protective effects, offering theoretical support for developing compound anti-inflammatory diet additives in aquaculture. - Source: PubMed
Publication date: 2026/10/01
Lin YijingHuang WeiChen PengWu ZhenhuaZhou HuihuiMai KangsenZhang Wenbing - Currently, colorectal cancer (CRC) remains a major global health challenge, with a rising incidence linked to a sedentary lifestyle and metabolic diseases, the main player being obesity (OB). Visceral adipose tissue (VAT) emerged as a key mediator of this association, functioning as a highly active endocrine-immune organ, rather than a mere energy reservoir. In OB, VAT undergoes pathological remodeling, including adipocyte hypertrophy and hypoxia, leading to a state of chronic low-grade inflammation. This review explores the mechanisms by which the dysfunctional VAT secretome orchestrates remodeling of the colorectal tumor microenvironment (TME). - Source: PubMed
Publication date: 2026/10/01
Stanciu Diana-IulianaHudiță ArianaGinghină OctavGălățeanu Bianca - Inflammatory bowel disease (IBD) frequently involves hepatobiliary complications linked to the gut-liver axis, yet dietary strategies targeting this pathway remain underexplored. We investigated the effects of dietary low-molar-mass oat β-glucan on hepatic redox balance and inflammatory cytokines in a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. Eighty-four male Sprague-Dawley rats were assigned to colitis or control groups, each fed a supplemented or non-supplemented diet for 3, 7, or 21 days. Hepatic total antioxidant status (TAS), lipid peroxidation (TBARS), superoxide dismutase (SOD), glutathione reductase (GR) and peroxidase (GPx) activities, and interleukin-1 (IL-1) and interleukin-6 (IL-6) concentrations were determined. In colitis animals, β-glucan progressively increased TAS and GR, maintained SOD at control levels, and reduced TBARS, GPx, IL-1, and IL-6, reaching control values by day 21. Under the tested conditions - a single low-molar-mass fraction (5.9 × 10 g/mol) at a single dietary level of 1% (w/w) - effects were time-dependent and inflammation-specific, with no modulation in healthy controls, supporting oat β-glucan of this molar mass as an adjunctive dietary strategy limiting extraintestinal hepatic complications of colitis. The dose- and molar-mass-dependence of the response remain to be established. - Source: PubMed
Publication date: 2026/10/01
Harasym JoannaWilczak JacekDziendzikowska KatarzynaGromadzka-Ostrowska Joanna - Nephrolithiasis, particularly calcium oxalate (CaOx) stones, remains a global health burden with limited pharmacological options for recurrence prevention. In this study, we investigated the therapeutic mechanism of acacetin (ACA) using both in vitro (COM-stimulated HK-2 cells) and in vivo (glyoxylate-induced mice) models of CaOx kidney stone. Our results demonstrated that ACA treatment dose-dependently attenuated renal injury, reduced the expression of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), and activated the Nrf2/HO-1/NQO1 antioxidant pathway. Moreover, ACA significantly suppressed the NLRP3/caspase-1/GSDMD-mediated pyroptosis pathway. Through network pharmacology analysis, molecular docking, and molecular dynamics simulations, we identified GPR35 as a high-affinity direct binding target of ACA. The cellular thermal shift assay (CETSA) further confirmed that ACA enhanced the thermal stability of GPR35, indicative of direct interaction. Functional validation revealed that GPR35 overexpression recapitulated the protective effects of ACA by inhibiting NLRP3-related pyroptosis, whereas GPR35 knockdown significantly abrogated ACA-mediated pyroptosis suppression. Collectively, these findings establish the GPR35/NLRP3/pyroptosis axis as a critical pathway in CaOx kidney stone pathogenesis and identify ACA as a novel GPR35 agonist that concurrently suppresses pyroptosis and activates antioxidant defenses. Thus, ACA represents a promising therapeutic candidate for the prevention and treatment of kidney stone disease. - Source: PubMed
Publication date: 2026/10/01
Jiang LeiXia QinHong ZhongwenGuo ZhuifengLiu ShuaiYu ShenggenYi JunyuChen BowenDuan NengliangGao YuchenLiu HuanZhang YukeChen QiXu Yunfei